MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

MeiraGTx Holdings plc

MeiraGTx is a clinical-stage genetic medicine company focused on developing potentially curative treatments for serious diseases. The company is pioneering technologies that allow precise control of gene expression using proprietary oral small molecules, with applications in treating inherited diseases and other conditions.

msh id	COM:MEIRAGTX
symbol	MGTX
name	MeiraGTx Holdings plc
homepage url	https://www.meiragtx.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	402
crunchbase url	-
linkedin url	-
founders	-

market cap	266.23M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.14
growth cost of revenue	0.57
growth depreciation and amortization	16.67
growth ebitda	-0.07
growth ebitda ratio	-0.21
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.02
growth gross profit	-0.96
growth gross profit ratio	-0.95

COM:MEIRAGTX

MeiraGTx

Last Close

5.82

21/11 21:00

Market Cap

266.23M

Beta: -

Volume Today

154.20K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	151.08M
cost of revenue	151.08M
depreciation and amortization	13.73M
ebitda	-123.33M
ebitda ratio	-8.8
eps	-1.49
eps diluted	-1.49
operating expenses	137.35M
operating income	-137.06M
operating income ratio	-9.78

accounts receivables	4.83M
capital expenditure	-20.17M
cash at beginning of period	115.52M
cash at end of period	129.57M
inventory	-
working capital ttm	40.02M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-